Literature DB >> 36068471

Pharmacogenetics of Antipsychotic Treatment in Schizophrenia.

Samar S M Elsheikh1, Daniel J Müller2,3, Jennie G Pouget1,4.   

Abstract

Antipsychotics are the mainstay treatment for schizophrenia. There is large variability between individuals in their response to antipsychotics, both in efficacy and adverse effects of treatment. While the source of interindividual variability in antipsychotic response is not completely understood, genetics is a major contributing factor. The identification of pharmacogenetic markers that predict antipsychotic efficacy and adverse reactions is a growing area of research and holds the potential to replace the current trial-and-error approach to treatment selection in schizophrenia with a personalized medicine approach.In this chapter, we provide an overview of the current state of pharmacogenetics in schizophrenia treatment. The most promising pharmacogenetic findings are presented for both antipsychotic response and commonly studied adverse reactions. The application of pharmacogenetics to schizophrenia treatment is discussed, with an emphasis on the clinical utility of pharmacogenetic testing and directions for future research.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Antipsychotics; Genetics; Pharmacogenetics; Response; Schizophrenia; Side effects

Mesh:

Substances:

Year:  2022        PMID: 36068471     DOI: 10.1007/978-1-0716-2573-6_14

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  167 in total

1.  Olanzapine: concordant response in monozygotic twins with schizophrenia.

Authors:  I Mata; V Madoz; M J Arranz; P Sham; R M Murray
Journal:  Br J Psychiatry       Date:  2001-01       Impact factor: 9.319

Review 2.  Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.

Authors:  S Kapur; P Seeman
Journal:  Am J Psychiatry       Date:  2001-03       Impact factor: 18.112

3.  Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study.

Authors:  S Gebhardt; F M Theisen; M Haberhausen; M Heinzel-Gutenbrunner; P M Wehmeier; J-C Krieg; W Kühnau; J Schmidtke; H Remschmidt; J Hebebrand
Journal:  J Clin Pharm Ther       Date:  2010-04       Impact factor: 2.512

4.  The path to personalized medicine.

Authors:  Margaret A Hamburg; Francis S Collins
Journal:  N Engl J Med       Date:  2010-06-15       Impact factor: 91.245

Review 5.  Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis.

Authors:  Diana O Perkins; Hongbin Gu; Kalina Boteva; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2005-10       Impact factor: 18.112

6.  Monozygotic twins concordant for response to clozapine.

Authors:  D Vojvoda; K Grimmell; M Sernyak; C M Mazure
Journal:  Lancet       Date:  1996-01-06       Impact factor: 79.321

7.  Familial psychosis and vulnerability to tardive dyskinesia.

Authors:  H Youssef; G Lyster; F Youssef
Journal:  Int Clin Psychopharmacol       Date:  1989-10       Impact factor: 1.659

8.  Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.

Authors:  J L McClay; D E Adkins; K Aberg; S Stroup; D O Perkins; V I Vladimirov; J A Lieberman; P F Sullivan; E J C G van den Oord
Journal:  Mol Psychiatry       Date:  2009-09-01       Impact factor: 15.992

9.  Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study.

Authors:  C Lavedan; L Licamele; S Volpi; J Hamilton; C Heaton; K Mack; R Lannan; A Thompson; C D Wolfgang; M H Polymeropoulos
Journal:  Mol Psychiatry       Date:  2008-06-03       Impact factor: 15.992

10.  Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches.

Authors:  Masashi Ikeda; Yasuyuki Tomita; Akihiro Mouri; Minori Koga; Tomo Okochi; Reiji Yoshimura; Yoshio Yamanouchi; Yoko Kinoshita; Ryota Hashimoto; Hywel J Williams; Masatoshi Takeda; Jun Nakamura; Toshitaka Nabeshima; Michael J Owen; Michael C O'Donovan; Hiroyuki Honda; Tadao Arinami; Norio Ozaki; Nakao Iwata
Journal:  Biol Psychiatry       Date:  2009-10-22       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.